Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced that its subsidiary, Pasithea Clinics, has opened a second clinical in Marylebone that offers intravenous ketamine therapy to patients with treatment-resistant mental health issues. The company had opened its maiden clinic in Knightsbridge, the UK, in October 2021.
Pasithea has a second clinic in London.
CEO Pasithea Therapeutics Dr. Tiago Reis Marques said, “Through our second London clinic, we are pleased to increase access to this important therapy for patients in the U.K. with treatment-resistant mental health disorders. More than ever, new treatment therapies are urgently needed for these patients and by broadening our coverage, we can work to close the treatment gap.”
Pasithea Clinics Managing Director in the UK Dr. Yasssine Bendiabdallah stated, “Two decades of research supports the efficacy of ketamine in improving symptoms experienced in some mental health disorders. With the opening of our Marylebone location, we are expanding our footprint in the U.K. and will continue to work toward bringing this treatment option to patients nationwide.”
Ketamine was approved almost five decades ago
Ketamine is a Food and Drug Administration (“FDA”) authorized anesthetic that was first offered to the medical world over 50 years ago. It has lately been repurposed for treating psychiatric problems at far lower levels than in anesthesia, and it is gaining traction as a possible treatment for mental health diseases. It has shown extraordinary efficacy and a rapid and prolonged effect in specific psychiatric diseases, including post-traumatic stress disorder (“PTSD”) and treatment-resistant depression (“TRD”)
According to the World Health Organization, major depression is the largest cause of long-term disability globally. Available therapies have low success rates, significant side effects, and a delay in action of several weeks. Studies indicate up to 70% of patients who get IV ketamine treatment will experience a clinical response. Although the number of treatments recommended varies by patient, a common treatment plan includes up to six infusions spaced two to three weeks apart.
The company has a team of experts that develops new molecular entities for neurological and psychiatric disorders treatment in-home care settings and clinics.
